In a Japanese Phase II study , the hepatitis C virus NS3/4A protease inhibitor simeprevir demonstrated potent antiviral activity and significantly improved sustained virologic response rates when added to peginterferon -2 a/ribavirin in treatment-nave patients infected with hepatitis C virus genotype 1 .